Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

DoD Seeks Manufacturer for Nerve Agent Anticonvulsant Autoinjectors

by Global Biodefense Staff
February 14, 2018
CBRN Military Readiness

U.S. Airmen don their gas masks during a chemical, biological, radiological or nuclear attack training exercise at Davis-Monthan Air Force Base, Ariz., Feb. 11, 2018. The CBRN exercise tested the readiness of Airmen in a simulated deployed location. Photo credit: Cheyenne A. Powers

The Joint Program Executive Office for Chemical and Biological Defense is seeking information on the capabilities of organizations to develop or manufacture a diazepam autoinjector with an anticonvulsant indication against organophosphate poisoning.

Offerors will serve as the Food and Drug Administration (FDA) sponsor for a diazepam autoinjector and would be responsible for product development, manufacturing, and regulatory requirements needed for FDA approval and compliance.

The DoD is currently the NDA holder for Diazepam Auto-Injector, (NDA #20-124), Convulsant Antidote for Nerve Agents (CANA) and is interested in retaining sponsorship. The government is seeking a manufacturing partner; a tech transfer will be arranged between the current manufacturer and the partner. In addition to cGMP production, the partner will be responsible for product recall and Adverse Event reporting and all post-marketing activities.

Nerve Agent Countermeasure Autoinjector Training
A British senior noncommissioned officer, with the Joint European Training Team, briefs members of the British armed forces, assigned to local units, how to use the autoinjector of nerve agent antidote during a chemical, biological, radiological and nuclear training on Chièvres Air Base, Belgium, Jan. 19, 2016. Photo credit: Pierre-Etienne Courtejoie

Each autoinjector contains 10 mg of diazepam in 2.0 mL total volume. Under the current diazepam autoinjector NDA, each mL contains 5 mg diazepam compounded with 40% propylene glycol, 10% ethyl alcohol, 5% sodium benzoate and benzoic acid as buffers, and 1.5% benzyl alcohol as preservative.

The Service Member-carried device must be administrable by personnel in Mission Oriented Protective Posture 4 (MOPP-4) over-garments and mask, to a casualty in MOPP-4. The delivery device platform and drug must be stable at operationally relevant temperatures to include temperature extremes experienced by Service Members in the field.

Additional requirements are detailed in FBO.gov Solicitation Number: W911QY-18-S-0004. Capability statements are due 9 March 2018.

Source: FBO.gov

Tags: Chemical WeaponsJPEO-CBRNDRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy